Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin - De Leeuw, I; Vague, P; Selam, J L (Diabetes Obes Metab, 2005)